BioSpace News Archive

Agilent Technologies Inc. announced that Professor Gerhardt Attard has been selected to receive a prestigious Agilent Thought Leader Award.

Lucid Diagnostics Inc. today announced that LucidDx Labs Inc. (“LucidDx Labs”), has entered into participating provider agreements with preferred provider organizations Prime Healthcare, Three Rivers Provider Network, and Galaxy Health Network (the “PPOs”), as well as Alivio Health, a specialized diagnostic laboratory network.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2022 financial results and provide a corporate update on Wednesday, August 10, 2022.

Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of KYZATREX™ (testosterone undecanoate) by the U.S. Food and Drug Administration (FDA). KYZATREX™ is an oral testosterone replacement therapy (“TRT”) indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2022 financial results on Tuesday, August 9th, 2022, before the financial markets open.

VBL Therapeutics, a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, announced an organizational streamlining designed to reduce operating expenses and preserve capital.

Compass Therapeutics, Inc. today announced it will present at the 2022 Wedbush PacGrow Healthcare Conference that will take place virtually August 9 – 10, 2022.

Satsuma Pharmaceuticals, Inc . today announced completion of subject enrollment in the Company’s ongoing STS101 SUMMIT pivotal Phase 3 efficacy trial, with more than 1,400 subjects randomized. Satsuma expects to announce topline results from the SUMMIT trial in the fourth quarter of 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2022 and provided recent business updates.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.